Advertisement

Drugs and Other Substances Interfering with Thyroid Function

  • Lucia MontanelliEmail author
  • Salvatore Benvenga
  • Laszlo Hegedüs
  • Paolo Vitti
  • Francesco Latrofa
  • Leonidas H. Duntas
Reference work entry
First Online:
  • 1.4k Downloads
Part of the Endocrinology book series (ENDOCR)

Abstract

Several drugs and supplements may interfere, at different levels, with regulation of thyroid function. Some drugs may also cause thyroid autoimmunity. This chapter reviews drugs that significantly affect thyroid function. Glucocorticoids, dopamine agonists, somatostatin analogs, and retinoids inhibit TSH secretion. Lithium, tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), antiepileptics, rifampin, metformin, and amiodarone mainly affect directly thyroid function. Interferon-α and antiretroviral drugs may have several effects, including inducing thyroid autoimmunity. The heterogeneous adverse effects induced by antineoplastic agents (cytotoxic and novel anticancer agents, tyrosine kinase inhibitors, bexarotene- and iodine-based cancer therapies, and radioimmunotherapies) will be highlighted. Immunoregulatory drugs (IL-2, denileukin diftitox, thalidomide and lenalidomide, IFN-α, alemtuzumab) and immune checkpoint inhibitors (anti-CTLA4 and anti-PD-1 monoclonal antibodies) mainly promote thyroid autoimmunity. The effects of endocrine disruptors and nutraceuticals and over-the-counter products (selenium, L-carnitine, thyroid hormones, iodine, and biotin) will also be discussed. The last part of the chapter concerns drugs that interfere with levothyroxine (LT4) absorption.

Keywords

Alemtuzumab Amiodarone Anti-CTLA4 monoclonal antibodies Anti-PD-1 monoclonal antibodies Bexarotene Cytotoxic agents Denileukin diftitox Dopamine Endocrine disruptors Glucocorticoids IFN-α IL-2 Immune checkpoint inhibitors Inositol Interferons L-carnitine Lenalidomide Levothyroxine sodium Lithium Metformin Nutraceuticals Rexinoids Rifampin Selective serotonin reuptake inhibitors Selenium Somatostatin Thalidomide Tricyclic antidepressants Tyrosine kinase inhibitors 
This is a preview of subscription content, log in to check access.

References

  1. Abelleira E, De Cross GA, Pitoia F. Thyroid dysfunction in adults infected by human immunodeficiency virus. Medicina (B Aires). 2014;74:315–20.Google Scholar
  2. Al-Alusi MA, Du L, Li N, Yeh MW, He X, Braverman LE, Leung AM. Metformin does not suppress serum thyrotropin by increasing levothyroxine absorption. Thyroid. 2015;25:1080–4.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Amico JA, Richardson V, Alpert B, Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med. 1984;144(3):487–90.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117(1):10–3.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Arena S, Latina A, Baratta R, Burgio G, Gullo D, Benvenga S. Chronic lymphocytic thyroiditis: could it be influenced by a petrochemical complex? Data from a cytological study in South-Eastern Sicily. Eur J Endocrinol. 2015;172:383–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988;318(24):1557–63.CrossRefGoogle Scholar
  7. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002;112(5):412–3.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12(5):399–405.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Barbesino G. Drugs affecting thyroid function. Thyroid. 2010;20(7):763–70.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Barbesino G. Misdiagnosis of graves’ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid. 2016;26(6):860–3.PubMedCrossRefPubMedCentralGoogle Scholar
  11. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves' Orbitopathy (EUGOGO). The 2016 European thyroid association/European group on graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Bauer M, BlumentrittH FR, Schlattmann P, Adli M, Baethge C, Bschor T, Müller-Oerlinghausen B, Berghöfer A. Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. J Affect Disord. 2007;104:45–51.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Benvenga S. When thyroid hormone replacement is ineffective? Curr Opin Endocrinol Diabetes Obes. 2013;20:467–77.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Benvenga S, Antonelli A. Inositol(s) in thyroid function, growth and autoimmunity. Rev Endocr Metab Disord. 2016;17(4):471–84.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Benvenga S, Lakshmanan M, Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid. 2000;10:1043–50.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Benvenga S, Lapa D, Cannavò S, Trimarchi F. Successive thyroid storms treated with L-carnitine and low doses of methimazole. Am J Med. 2003;115:417–8.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Benvenga S, Amato A, Calvani M, Trimarchi F. Effects of carnitine on thyroid hormone action. Ann N Y Acad Sci. 2004;1033:158–67.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Benvenga S, Antonelli A, Thyroid VR. nodules and thyroid autoimmunity in the context of environmental pollution. Rev Endocr Metab Disord. 2015;16:319–40.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Benvenga S, Vigo MT, Metro D, Granese R, Vita R, Le Donne M. Type of fish consumed and thyroid autoimmunity in pregnancy and postpartum. Endocrine. 2016;52:120–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Benvenga S, Vicchio T, Di Bari F, Vita R, Fallahi P, Ferrari SM, Catania S, Costa C, Antonelli A. Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto’s thyroiditis: preliminary in vitro studies. Eur Rev Med Pharmacol Sci. 2017;21(2 Suppl):89–101.PubMedPubMedCentralGoogle Scholar
  21. Berens SC, Wolff J, Murphy DL. Lithium concentration by the thyroid. Endocrinology. 1970;87(5):1085–7.PubMedCrossRefPubMedCentralGoogle Scholar
  22. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health. 2006;2:23.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Investig. 2007;30(5):363–6.CrossRefGoogle Scholar
  24. Bogazzi F, Bartalena L, Brogioni S, Mazzeo S, Vitti P, Burelli A, Bartolozzi C, Martino E. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid. 1997;7(4):541–5.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999;84(2):499–503.PubMedPubMedCentralGoogle Scholar
  26. Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F, Rossi G, Lippi F, Pinchera A, Martino E. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab. 2002;87(10):4490–5.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Bogazzi F, Bartalena L, Tomisti L, Dell'Unto E, Cosci C, Sardella C, Tanda ML, Lai A, Gasperi M, Aghini-Lombardi F, Martino E. Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy. J Endocrinol Investig. 2008;31(6):515–9.CrossRefGoogle Scholar
  28. Bogazzi F, Tomisti L, Bartalena L, Martino E. Amiodarone-induced thyrotoxicosis. In: Matfin G, editor. Endocrine and metabolic medical emergencies. Washington, DC: Endocrine Press; 2014.Google Scholar
  29. Brabant A, Brabant G, Schuermeyer T, Ranft U, Schmidt FW, Hesch RD, von Zur Muhlen A. The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinol. 1989;121:95–100.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Braun D, Kim TD, le Coutre P, Köhrle J, Hershman JM, Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab. 2012;97(1):E100–5.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Cappelli C, Rotondi M, Pirola I, Agosti B, Formenti AM, De Cata P, Salvetti M, Chiovato L, Castellano M. Metformin-induced thyrotropin suppression is not associated with cardiac effects. Hormones (Athens). 2014;13:252–8.CrossRefGoogle Scholar
  32. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89(8):3656–61. Review.PubMedCrossRefPubMedCentralGoogle Scholar
  33. Carvalho LG, TeixeiraPde F, Panico AL, Cohen MV, Pinheiro MF, Barroso PF, Vaisman M. Evaluation of thyroid function and autoimmunity in HIV-infected women. Arq Bras Endocrinol Metabol. 2013;57:450–6.PubMedCrossRefPubMedCentralGoogle Scholar
  34. Christensen HR, Simonsen K, Hegedüs L, Hansen BM, Døssing M, Kampmamn JP, Hansen JM. Influence of rifampicin on thyroid gland volume, thyroid hormones, and antipyrine metabolism. Acta Endocrinol. 1989;121(3):406–10.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069–78.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Colucci PH, Seng Yue C, Ducharme M, Benvenga S. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2013;9:40–7.CrossRefGoogle Scholar
  37. Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011 Aug 9;77(6):573–9.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017;8(5):8910–20.PubMedCrossRefPubMedCentralGoogle Scholar
  39. D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017;24:31–7. Review.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15(4):1043–53.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99:80–9.PubMedPubMedCentralCrossRefGoogle Scholar
  42. de Carvalho GA, Bahls SC, Boeving A, Graf H. Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. Thyroid. 2009;19:691–7.PubMedCrossRefPubMedCentralGoogle Scholar
  43. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37(5):499–507.PubMedCrossRefPubMedCentralGoogle Scholar
  44. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, SotoAM ZRT, Gore AC. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev. 2009;30:293–42.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Díez JJ, Iglesias P. An analysis of the relative risk for goiter in euthyroid patients with type 2 diabetes. Clin Endocrinol. 2014;80(3):356–61.CrossRefGoogle Scholar
  46. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465–70.PubMedCrossRefPubMedCentralGoogle Scholar
  47. Duntas LH. Chemical contamination and the thyroid. Endocrine. 2015;48(1):53–64.PubMedCrossRefPubMedCentralGoogle Scholar
  48. Duntas LH, Benvenga S. Selenium: an element for life. Endocrine. 2015;48:756–75.PubMedCrossRefPubMedCentralGoogle Scholar
  49. Eker SS, Akkaya C, Sarandol A, Cangur S, Sarandol E, Kirli S. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;15(32):955–61.CrossRefGoogle Scholar
  50. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Factitious graves’ disease due to biotin immunoassay interference – A case and review of the literature. J Clin Endocrinol Metab. 2016;101:3251–5.PubMedCrossRefPubMedCentralGoogle Scholar
  51. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735–51.PubMedCrossRefPubMedCentralGoogle Scholar
  52. Ferrara R, Ientile V, Arcoraci V, Ferrajolo C, Piccinni C, Fontana A, Benvenga S, Trifirò G. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015. Endocrine. 2017;58(1):143–52.PubMedCrossRefPubMedCentralGoogle Scholar
  53. Figaro MK, Clayton Jr W, Usoh C, Brown K, Kassim A, Lakhani VT, Jagasia S. Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol. 2011;86(6):467–70.PubMedCrossRefPubMedCentralGoogle Scholar
  54. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, Pol S. Hepatitis activity index is a key factor in determining the natural history of chronichepatitis C. Hum Pathol. 2001;32(9):904–9.PubMedCrossRefPubMedCentralGoogle Scholar
  55. Ganne-Carrie N, Medini A, Coderc E, Seror O, Christidis C, Grimbert S, Trinchet JC, Beaugrand M. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun. 2000;14(2):189–93.PubMedCrossRefPubMedCentralGoogle Scholar
  56. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006;91(6):2205–8.PubMedCrossRefPubMedCentralGoogle Scholar
  57. González-Rodríguez E, Rodríguez-Abreu D. Spanish group for cancer immuno-biotherapy (GETICA) immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21(7):804–16.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Graeppi-Dulac J, Vlaeminck-Guillem V, Perier-Muzet M, Dalle S, Orgiazzi J. The impact of retinoids on the thyroid axis. Eur J Endocrinol. 2014;170:R253–62.PubMedCrossRefPubMedCentralGoogle Scholar
  59. Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol. 2008;69(4):669–72.CrossRefGoogle Scholar
  60. Hamed SA. The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol. 2015;8:74150.Google Scholar
  61. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011;103(21):1572–87.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23:793–800.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Hegedüs L, Hansen JM, Lühdorf K, Perrild H, Feldt-Rasmussen U, Kampmann JP. Increased frequency of goiter in epileptic patients on long-term phenytoin or carbamazepine treatment. ClinEndocrinol (Oxf). 1985;23(4):423–9.CrossRefGoogle Scholar
  64. Hoang TD, Mai VQ, Clyde PW, Shakir MK. Over-the-counter-drug-induced thyroid disorders. Endocr Pract. 2013;19:268–74.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983;106(4 Pt 2):840–7.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol. 1999;50(4):503–9.CrossRefGoogle Scholar
  67. Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014;171(3):R91–9.PubMedCrossRefPubMedCentralGoogle Scholar
  68. Jarry H, Christoffel J, Rimoldi G, Koch L, Wuttke W. Multi-organic endocrine disrupting activity of the UV screen benzophenone 2 (BP2) in ovariectomized adult rats after 5 days treatment. Toxicology 2004;205(1-2):87–93.PubMedCrossRefPubMedCentralGoogle Scholar
  69. Johnston BA. One-third of nation’s adults use herbal remedies: market estimated at 3.2 billion. Herbal Gram. 1997;(40):49. American Botanical Council.Google Scholar
  70. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 2011;96(10):3087–94.PubMedPubMedCentralCrossRefGoogle Scholar
  71. Kim HI, Kim TH, Kim H, Kim YN, Jang HW, Chung JH, Moon SM, Jhun BW, Lee H, Koh WJ, Kim SW. Effect of rifampin on thyroid function test in patients on levothyroxine medication. PLoS One. 2017;12(1):e0169775.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord. 2005;87:313–7.PubMedCrossRefPubMedCentralGoogle Scholar
  73. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997;7(6):891–6.CrossRefGoogle Scholar
  74. Köhrle J. Environment and endocrinology: the case of thyroidology. Ann Endocrinol (Paris). 2008;69:116–22.CrossRefGoogle Scholar
  75. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol. 1995;18(4):272–8.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):723–33.PubMedPubMedCentralCrossRefGoogle Scholar
  77. Lazarus JH, McGregor AM, Ludgate M, Darke C, Creagh FM, Kingswood CJ. Effect of lithium carbonate therapy on thyroid immune status in manic depressive patients: a prospective study. J Affect Disord. 1986;11(2):155–60.PubMedCrossRefPubMedCentralGoogle Scholar
  78. Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab. 2010;21:676–83.PubMedCrossRefPubMedCentralGoogle Scholar
  79. Leung AM, Pearce EN, Braverman LE. Environmental perchlorate exposure: potential adverse thyroid effects. Curr Opin Endocrinol Diabetes Obes. 2014;21:372–6.PubMedPubMedCentralCrossRefGoogle Scholar
  80. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. Myelodysplastic syndrome-003 study investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.PubMedCrossRefPubMedCentralGoogle Scholar
  81. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab. 2009;23:781–92.PubMedCrossRefPubMedCentralGoogle Scholar
  82. Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu GL, Farci P, Orgiana G, Balestrieri A, Cocco PL, Mariotti S. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia. J Endocrinol Investig. 1999;22(9):660–5.CrossRefGoogle Scholar
  83. Lupoli R, Di Minno A, Tortora A, Ambrosino P, Lupoli GA, Di Minno MN. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab. 2014;99:E143–8.PubMedCrossRefPubMedCentralGoogle Scholar
  84. Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 2013;23(2):151–9.PubMedCrossRefPubMedCentralGoogle Scholar
  85. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92(9):3531–4.PubMedCrossRefPubMedCentralGoogle Scholar
  86. Marini H, Polito F, Adamo EB, Bitto A, Squadrito F, Benvenga S. Update on genistein and thyroid: an overall message of safety. Front Endocrinol (Lausanne). 2012;3:94.Google Scholar
  87. Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res 1987a;26(1–4):158–171; iPubMedCrossRefPubMedCentralGoogle Scholar
  88. Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Lenziardi M, Ceccarelli C, Bambini G, Safran M, Braverman LE, Pinchera A. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol. 1987b;26(2):227–37.CrossRefGoogle Scholar
  89. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240–54.PubMedPubMedCentralGoogle Scholar
  90. McElnea E, Ní Mhéalóid A, Moran S, Kelly R, Fulcher T. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit. 2014;33(6):424–7.PubMedCrossRefPubMedCentralGoogle Scholar
  91. Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Investig. 2011;34(1):78–84.CrossRefGoogle Scholar
  92. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164(2):303–7.PubMedCrossRefPubMedCentralGoogle Scholar
  93. Mitchell AL, Hickey B, Hickey JL, Pearce SHS. Trends in thyroid hormone prescribing and consumption in the UK. BMC Health. 2009;9:132–41.CrossRefGoogle Scholar
  94. Müssig K, Thamer C, Bares R, Lipp HP, Häring HU, Gallwitz B. Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea. J Gen Intern Med. 2006;21:C11–4.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8(2):e55364.PubMedPubMedCentralCrossRefGoogle Scholar
  96. Negro R, Greek G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007;92:1263–8.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Nordio M, Pajalich R. Combined treatment with myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis. J Thyr Research. 2013;2013:424163.Google Scholar
  98. Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S. Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved? Thyroid. 2015;25(11):1255–61.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Perrild H, Hegedüs L, Arnung K. Sex related goitrogenic effect of lithium carbonate in healthy young subjects. ActaEndocrinol (Copenh). 1984;106(2):203–8.Google Scholar
  100. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13(6):547–51.PubMedPubMedCentralCrossRefGoogle Scholar
  101. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab. 1986;62(3):563–8.PubMedCrossRefPubMedCentralGoogle Scholar
  102. Salem AK, Fenton MS, Marion KM, Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid. 2008;18(6):631–5.PubMedCrossRefPubMedCentralGoogle Scholar
  103. Sarne D. Effects of the environment, chemicals and drugs on thyroid function. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, Mc Lachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. Endotext [Internet]. South Dartmouth (MA): MD Text.com, Inc; 2016. p. 2000–10.Google Scholar
  104. Sauvage MF, Marquet P, Rousseau A, Raby C, Buxeraud J, Lachâtre G. Relationship between psychotropic drugs and thyroid function: a review. Toxicol Appl Pharmacol. 1998;149:127–35.PubMedCrossRefPubMedCentralGoogle Scholar
  105. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin Lymphoma. 2003;3:249–52.PubMedCrossRefPubMedCentralGoogle Scholar
  106. Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386:461–8.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Smit JW, Stokkel MP, Pereira AM, Romijn JA, Visser TJ. Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. J Clin Endocrinol Metab. 2007;92(7):2496–9.PubMedCrossRefPubMedCentralGoogle Scholar
  108. Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375:1552–65.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Spaulding SW, Burrow GN, Bermudez F, Himmelhoch JM. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab. 1972;35(6):905–11.PubMedCrossRefPubMedCentralGoogle Scholar
  110. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med. 1995;333(25):1688–94.PubMedCrossRefPubMedCentralGoogle Scholar
  111. Takasu N, Takara M, Komiya I. Rifampin-induced hypothyroidism in patients with Hashimoto's thyroiditis. N Engl J Med. 2005;352:518–9.PubMedCrossRefPubMedCentralGoogle Scholar
  112. Takasu N, Kinjou Y, Kouki T, Takara M, Ohshiro Y, Komiya I. Rifampin-induced hypothyroidism. J Endocrinol Investig. 2006;29(7):645–9.CrossRefGoogle Scholar
  113. Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid. 2013;23(11):1345–66.PubMedPubMedCentralCrossRefGoogle Scholar
  114. Trifirò G, Parrino F, Sultana J, Giorgianni F, Ferrajolo C, Bianchini E, Medea G, Benvenga S, Cricelli I, Cricelli C, Lapi F. Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice. Clin Drug Investig. 2015;35(3):187–95.PubMedCrossRefPubMedCentralGoogle Scholar
  115. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91(5):507–11.PubMedCrossRefPubMedCentralGoogle Scholar
  116. Verloop H, Smit JW, Dekkers OM. Sorafenib therapy decreases the clearance of thyrotropin. Eur J Endocrinol. 2013;168(2):163–7.PubMedCrossRefPubMedCentralGoogle Scholar
  117. Verrotti A, Scardapane A, Manco R, Chiarelli F. Antiepileptic drugs and thyroid function. J Pediatr Endocrinol Metab. 2008;21:401–8.PubMedCrossRefPubMedCentralGoogle Scholar
  118. Viniol A, Bösner S, Baum E, Donner-Banzhoff N. Forgotten drugs: long-term prescriptions of thyroid hormones – a cross-sectional study. Int J Gen Med. 2013;26(6):329–34.CrossRefGoogle Scholar
  119. Virili C, Trimboli P, Romanelli F, Centanni M. Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine. 2016;54(1):3–14.PubMedCrossRefPubMedCentralGoogle Scholar
  120. Vita R, Fallahi P, Antonelli A, Benvenga S. The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin Drug Deliv. 2014;11:1103–11.PubMedCrossRefPubMedCentralGoogle Scholar
  121. Vos F, Pieters G, Keuter M, van der Ven A. Graves’ disease during immune reconstitution in HIV-infected patients treated with HAART. Scand J Infect Dis. 2006;38:124–6.PubMedCrossRefPubMedCentralGoogle Scholar
  122. Wagner CE, Jurutka PW, Marshall PA, Heck MC. Retinoid X receptor selective agonists and their synthetic methods. Curr Top Med Chem. 2017;17(6):742–67.PubMedCrossRefPubMedCentralGoogle Scholar
  123. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol. 1998;157(1):5–12.PubMedCrossRefPubMedCentralGoogle Scholar
  124. Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, Lentjes E, Van Rood JJ, Cleton FJ, Osanto S. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993;11(7):1376–83.PubMedCrossRefPubMedCentralGoogle Scholar
  125. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.PubMedCrossRefPubMedCentralGoogle Scholar
  126. Willis M, Robertson NP. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2014;13:1115–24.PubMedCrossRefPubMedCentralGoogle Scholar
  127. Winther KH, Bonnema S, Hegedüs L. Is selenium supplementation in autoimmune thyroid diseases justified? Curr Opin Endocrinol Diabetes Obes. 2017;24(5):348–55.PubMedCrossRefPubMedCentralGoogle Scholar
  128. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448–54.PubMedPubMedCentralCrossRefGoogle Scholar
  129. Wu Q, Rayman MP, Lv H, Schomburg L, Cui B, Gao C, Chen P, Zhuang G, Zhang Z, Peng X, Li H, Zhao Y, He X, Zeng G, Qin F, Hou P, Shi B. Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab. 2015;100(11):4037–47.PubMedPubMedCentralCrossRefGoogle Scholar
  130. Yılmaz U, Yılmaz TS, Akıncı G, Korkmaz HA, Tekgül H. The effect of antiepileptic drugs on thyroid function in children. Seizure. 2014;23:29–35.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Lucia Montanelli
    • 1
    Email author
  • Salvatore Benvenga
    • 2
  • Laszlo Hegedüs
    • 3
  • Paolo Vitti
    • 5
  • Francesco Latrofa
    • 1
  • Leonidas H. Duntas
    • 4
  1. 1.Department of Clinical and Experimental Medicine, Endocrinology Unit 1University Hospital of PisaPisaItaly
  2. 2.Department of Clinical and Experimental Medicine, Master Program of Childhood, Adolescent and Women’s Endocrine Health, Interdepartmental Program of Molecular and Clinical Endocrinology, and Women’s Endocrine HealthUniversity of Messina and A.O.U. Policlinico G. MartinoMessinaItaly
  3. 3.Department of Endocrinology and MetabolismOdense University HospitalOdenseDenmark
  4. 4.Evgenideion Hospital, Unit of Endocrinology, Diabetes and MetabolismUniversity of AthensAthensGreece
  5. 5.Department of EndocrinologyUniversity of PisaPisaItaly

Personalised recommendations

Cite entry